Novo Nordisk ® es in the US in the first quarter of our portfolio TRx share 60% 40% US GLP-1 TRx market share Class growth ~60% Total GLP-1 scripts (millions) 6 52.9% 5 40.9% 4 29.8% 3 20% 0% Apr 2021 ulaglutide tirzepatide Total monthly GLP-1 scripts 16.3% 2 7.2% 1 4.7% 0 Apr 2023 esents a rolling four-week average
Download PDF file